Recombinant Human Brain Natriuretic Peptide for the Recovery Stage of Septic Shock: An Interventional Pilot Study (rh-BNP-RSS)

NCT06745206 NA NOT_YET_RECRUITING

As infection control improves and circulation stabilizes, treatment de-escalation of septic shock begins, accompanied by fluid redistribution from interstitial spaces to the vasculature, increasing cardiac volume load. Synthetic recombinant human BNP (rh-BNP) plays a role in inducing vasodilation, particularly in the venous system, alleviating cardiac congestion, and enhancing natriuresis and diuresis. Thus the investigators designed a single-center, prospective physiological study to evaluate the efficacy of standard rh-BNP infusion in reducing venous return and enhancing fluid removal, with a secondary objective of assessing the maintenance of perfusion pressure and tissue perfusion.

Details

Lead sponsor	Sichuan Provincial People's Hospital
Phase	NA
Status	NOT_YET_RECRUITING
Enrolment	30
Start date	2025-12
Completion	2026-09

Conditions

• Sepsis-induced Cardiomyopathy
• the Recovery Phase of Septic Shock

Interventions

• Lyophilized Recombinant Human Brain Natriuretic Peptide

Primary outcomes

• The pressure gradient of venous return — From baseline to 30 minutes after rh-BNP initiation.
  Pmsf - CVP